The decision starts with your knee's MRI pattern

The right question is not which injection is better — it is which structural problem your MRI actually shows.

Two patterns matter. A focal chondral defect is a discrete, contained lesion: a localised area where cartilage has been lost or damaged, often from a previous injury, while the surrounding joint remains reasonably intact. That is the pattern ChondroFiller™ addresses — a biodegradable collagen scaffold that gels within the defect and supports the body's own repair processes through acellular matrix-induced chondrogenesis. Arthrosamid® targets a fundamentally different picture: diffuse cartilage thinning accompanied by synovial inflammation — the whole-joint environment of established knee OA. It does not repair or regenerate cartilage; it integrates with the synovial lining and appears to modulate synovial inflammation to deliver sustained pain relief.

Some patients present with both patterns simultaneously — focal damage overlaid on background OA — and that combination makes the decision considerably more complex than a straight either/or. Specialist review is essential in those cases.

Before any injection is discussed, an MRI read by someone experienced in cartilage grading is the practical starting point. If you are considering assessment at Lincolnshire Knee's Sleaford clinic, onMRI™ AI-assisted analysis — including T2 mapping and cartilage segmentation — can help clarify which pattern is dominant and whether one or both products merit discussion.

ChondroFiller as an injectable scaffold for focal cartilage defects

ChondroFiller™ is a CE-marked Class III medical device — a Type I/III acellular collagen scaffold manufactured by Meidrix Biomedicals — that is delivered as an ultrasound-guided outpatient injection directly into a mapped cartilage defect. At body temperature it transitions from liquid to gel within minutes, filling the lesion space and establishing a three-dimensional matrix.

The clinical mechanism is acellular matrix-induced chondrogenesis. Progenitor cells from the surrounding synovium and underlying subchondral bone migrate into the collagen scaffold and, over the following 6–12 months, begin depositing new cartilage-like matrix. The product itself is biologically native and biodegradable — the joint progressively integrates and remodels it rather than accommodating a permanent foreign body. That distinction matters to patients weighing it against non-biodegradable options: the scaffold is designed to be replaced by the patient's own tissue rather than to remain indefinitely.

Published clinical outcomes across more than 19,000 procedures show an International Knee Documentation Committee (IKDC) score improvement of approximately 30 points at 12 months in knee use, with MOCART MRI regeneration scores — a validated measure of cartilage fill quality — in the range of 70–87. Reoperation rates of 3–8% and a complaint rate of approximately 0.06% have been reported in the wider clinical database. These figures are encouraging and reflect a maturing evidence base, though outcomes vary with defect size, location, and the condition of surrounding cartilage.

Patient selection relies on confirming a focal, contained lesion on MRI with reasonably preserved adjacent tissue. There is no published upper age or defect-size limit, making the pathway relevant to a broader group than is sometimes assumed.

How Arthrosamid manages pain in established knee OA

Arthrosamid® is a single-injection, permanent polyacrylamide hydrogel — 2.5% cross-linked polymer, 97.5% water — licensed for knee OA pain management in adults. It does not repair or regenerate cartilage; its purpose is different in kind from the scaffold approach described in the preceding section.

The 6 mL intra-articular injection integrates with the synovial lining of the knee capsule, where it forms a lasting volume cushion and appears to modulate synovial inflammation — a process closely linked to pain severity in OA. Whether the dominant effect is mechanical, anti-inflammatory, or both is still being formally investigated: an NHS-funded study at the Robert Jones and Agnes Hunt Orthopaedic Hospital (RJAH), backed by a £150,000 grant from Contura Orthopaedics, is the first UK programme designed to determine precisely how iPAAG acts in the joint and which patient subgroups respond best. A separate published case series (Maulana, Cole, Lee, J Arthritis, 2022) reported reduction in patellofemoral bone marrow lesions following a single injection, raising the possibility of structural effects beyond cushioning — an intriguing signal that warrants further investigation before it can be treated as an established outcome.

On clinical effectiveness, the picture is reasonably clear. Bliddal et al. (J Orthop Surg Res, 2024;19(1):274) published 12-month open-label data demonstrating meaningful pain reduction from approximately week 4, with sustained improvement sustained at one year. Manufacturer-cited follow-up data suggest benefit extending to three years. One safety point warrants straightforward mention: the true rate of inflammatory joint effusion after injection is likely higher than trial-reported figures, because some studies captured this adverse event through patient-reported 'sensation of distension' rather than clinical examination or imaging. Patients should raise this with their clinician before proceeding.

The permanence of the hydrogel is the practical consideration patients most often weigh. Unlike a biodegradable scaffold, Arthrosamid remains in the joint indefinitely and cannot be remodelled by the body's own tissue. For a patient with established, diffuse knee OA who has not found lasting relief from conventional injections and wants to avoid or delay surgery, that trade-off — sustained pain management from a single outpatient injection, accepted alongside a permanent implant — represents a mainstream clinical option with a growing published record. The open questions around mechanism and optimal patient selection are real, but they sit alongside, not against, that assessment.

Clinical evidence for each treatment, side by side

No trial has placed ChondroFiller™ and Arthrosamid® in direct comparison — patients and clinicians are therefore drawing on two separate, non-overlapping evidence streams.

For Arthrosamid, those streams are formally structured: two published open-label studies (at 6 and 12 months), a growing body of real-world data extending to three years, and an active NHS-funded randomised controlled trial. That combination represents a relatively mature published record for a product licensed as recently as 2021. The gaps that remain are methodological: some adverse-event reporting relied on patient self-report rather than clinical examination, and the patient subgroup most likely to achieve meaningful benefit has not yet been formally defined.

ChondroFiller's evidence base rests on a different foundation — a large procedural footprint with consistent patient-reported and MRI outcome scores across a broad clinical database. That volume is meaningful, but long-term data for the ultrasound-guided injection route specifically remain limited beyond 12–24 months. No RCT has been conducted in the injection-only pathway.

Both products are CE-marked Class III medical devices rather than pharmaceutical products. This distinction shapes how post-market safety data are collected and how long-term surveillance is structured; neither is held to the randomised trial standard required for drug licensing.

Neither product can currently claim superiority over the other in any formal comparative sense. The evidence that exists is specific to each product's intended structural target — a difference that makes direct comparison premature rather than merely absent.

When your knee shows both focal damage and widespread OA

Occasionally, an MRI reveals something messier: a contained focal chondral lesion sitting inside a joint that also shows the diffuse cartilage thinning and synovial changes of established OA. Neither product maps neatly onto this picture, and neither was studied in it.

A sequenced approach — addressing the focal defect first with the collagen scaffold, then managing ongoing synovitis with the permanent hydrogel once the regenerative phase is complete — is mechanistically coherent and is discussed clinically. The two treatments operate through entirely different mechanisms: ChondroFiller™ as a biodegradable regenerative scaffold that recruits the patient's own progenitor cells into a collagen matrix; Arthrosamid® as a permanent volume agent that integrates with the synovial lining and modulates inflammation. Conflating them as two versions of a 'filler' misrepresents how each works and why sequence would matter. That said, no published trial has studied this combination, and no formal combined-use protocol exists — a sequenced plan remains a clinical judgement, not a validated pathway.

The practical signal that makes this question worth raising with a specialist is an MRI that shows a scoreable focal defect alongside evidence of synovial thickening or bone marrow change in the surrounding joint. Where that combination is present, determining which finding is the dominant pain driver — and whether, or in what order, each might be addressed — requires a detailed assessment before any injection plan is confirmed.

Assessment, costs, and booking at Lincolnshire Knee

Determining which pathway — or which sequence — is appropriate begins with a structured consultation. Lincolnshire Knee accepts patients without a GP referral at its Sleaford (NG34) and Grantham (NG31) sites, with no NHS-style waiting list.

The initial assessment combines clinical history and functional goals with MRI review. Where cartilage status is central to the decision, onMRI™ AI-assisted cartilage analysis is available to support interpretation of defect location, depth, and surrounding tissue quality.

Both ChondroFiller™ and Arthrosamid® are self-funded; neither follows a routine NHS or standard PMI reimbursement pathway in the UK. As a guide, costs start from approximately £3,000 — the precise figure depends on the injection pathway recommended and is confirmed at consultation.

Book an assessment at lincolnshireknee.co.uk.